Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obstructive Sleep Apnea – Pipeline Review, H2 2016, provides an overview of the Obstructive Sleep Apnea (Respiratory) pipeline landscape.
Obstructive sleep apnea is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. Signs and symptoms of obstructive sleep apnea include excessive daytime sleepiness, awakening with chest pain, morning headache, high blood pressure, awakening with a dry mouth. Risk factors include being overweight, hypertension, diabetes, gender, smoking and family history.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obstructive Sleep Apnea – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obstructive Sleep Apnea (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.Obstructive Sleep Apnea.
Obstructive Sleep Apnea (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obstructive Sleep Apnea (Respiratory). - The pipeline guide reviews pipeline therapeutics for Obstructive Sleep Apnea (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Obstructive Sleep Apnea (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Obstructive Sleep Apnea (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Obstructive Sleep Apnea (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Obstructive Sleep Apnea (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Obstructive Sleep Apnea (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
340 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025, driven by rising awareness over the growing problem of osteoporosis and the ensuing emphasis on early diagnosis and treatment. With the percentage share of people aged 60 plus in the global population mix forecast...
125 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Clostridium Difficile Treatment Market to Reach $1.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Clostridium Difficile Treatment estimated at US$878.9 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 5.1% over the...
268 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Tuberculosis Therapeutics Market to Reach $1.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Tuberculosis Therapeutics estimated at US$979 Million in the year 2020, is projected to reach a revised size of US$1.3 Billion by 2027, growing at aCAGR of 3.6% over the period 2020-2027....
172 pages •
By Global Industry Analysts
• Apr 2021
Abstract:
- Global Overactive Bladder (OAB) Therapeutics Market to Reach $3.4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Overactive Bladder (OAB) Therapeutics estimated at US$3.2 Billion in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at aCAGR of 0.9%...
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
Acne Therapeutics Market Report Overview Acne Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Acne Therapeutics market types and applications. It is a focused study on Acne Therapeutics market space including global and...
Anti-tuberculosis Therapeutics Market Report Overview Anti-tuberculosis Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Anti-tuberculosis Therapeutics market types and applications. It is a focused study on Anti-tuberculosis...
Blood Disorder Therapeutics Market Report Overview Blood Disorder Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Blood Disorder Therapeutics market types and applications. It is a focused study on Blood Disorder Therapeutics...
Crohn’s Disease Diagnostics and Therapeutics Market Report Overview Crohn’s Disease Diagnostics and Therapeutics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Crohn’s Disease Diagnostics and Therapeutics market types and applications....
Therapy
Digestive System Disorder
Diagnostics
World
Health Provider Density
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.